GSK plc (GSK.L)
| Previous Close | 1,673.00 |
| Open | 1,685.50 |
| Bid | 1,702.50 x 0 |
| Ask | 1,703.50 x 0 |
| Day's Range | 1,673.00 - 1,707.00 |
| 52 Week Range | 1,302.60 - 1,725.81 |
| Volume | |
| Avg. Volume | 8,416,856 |
| Market Cap | 69.626B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 14.20 |
| EPS (TTM) | 1.20 |
| Earnings Date | May 01, 2024 |
| Forward Dividend & Yield | 0.64 (3.83%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | N/A |
Evening StandardFTSE 100 Live 1 May: GSK, Next and Smith & Nephew in focus, shares edge up before Fed call
Upgraded profit guidance by GSK stood out today in a session featuring updates by Next, Smith & Nephew and Sensodyne business Haleon. The quartet all signalled robust trading at the start of 2024, helping the FTSE 100 index to begin May in resilient fashion. Traders are also looking ahead to tonight’s US Federal Reserve decision and whether September is still the most likely month for the first cut.
ReutersGSK raises 2024 profit forecast but says sales growth to slow in 2nd half
(Reuters) -GSK raised its full-year profit forecast on Wednesday on strong demand for vaccines and specialty medicines though it noted sales growth would slow in the second half. CEO Emma Walmsley's strategy has focussed on vaccines and infectious diseases and a shift in its HIV focus to long-acting treatment and prevention therapies. It expects 2024 sales to grow in the upper end of its 5% to 7% forecast range.
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
